Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC. By Caroline Seymour. October 24th 2024. Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.
LUNG CANCER - Targeted Oncology
SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes. Jordyn Sava. September 30th 2024. Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.
Breast Cancer | Oncology News & Insights - Targeted Oncology
Nov 1, 2024 · Participants Consider the Necessity of Chemo in HER2+ Breast Cancer. Targeted Oncology Staff. August 22nd 2024. During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Checkpoint Inhibition and Targeted Therapy Move the Needle in ...
1 day ago · Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer. Atezolizumab (Tecentriq) plus targeted therapy demonstrated longer median overall survival (OS) compared with historic controls in patients with anaplastic thyroid cancer, according to ...
Less Toxic, More Personalized Treatments on the Horizon in …
Sep 12, 2024 · The APT trial was a single-arm, phase 2 trial evaluating patients with node-negative, HER2-positive breast cancer measuring 3 cm or less who received paclitaxel weekly for 12 weeks in combination with trastuzumab for 1 year.1 The final planned analysis of the APT trial showed a 10-year invasive disease-free survival of 91.3% with trastuzumab.
Targeted Therapies in Oncology - Targeted Oncology
January 2023. Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA …
Prostate Cancer - Targeted Oncology
Apa-RP Study Suggests Potential for Apalutamide and ADT in Prostate Cancer. Expert Analyzes Efficacy/Safety Data for Apalutamide and ADT in Prostate Cancer. 100% BCR-Free at 2 Years: Promising Early Results for High-Risk Prostate Cancer. Studying Apalutamide With ADT in High-Risk Localized Prostate Cancer.
News - Targeted Oncology
Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer. Sabrina Serani. November 6th 2024. Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.
Melanoma - Targeted Oncology
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4. Targeted Oncology Staff. July 16th 2024. During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second ...
About Us - Targeted Oncology
About Us. Through our digital and print media platforms, Targeted Healthcare Communications offers a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology. Targeted Therapies in Oncology is dedicated to providing oncology healthcare professionals with leading edge research ...